Clinical Trial News and Research

RSS

Substituting meat for mycoprotein reduces intestinal genotoxins, increases healthy gut bacteria

Researchers from Northumbria University have found that swapping red and processed meat for Quorn's mycoprotein, a fungi-based meat alternative, leads to a significant reduction in intestinal genotoxins - which can cause bowel cancer - and increases healthy gut bacteria.

17 Feb 2023

Effect of prune supplementation on the gut microbiome of postmenopausal women

New research published in the journal Food & Function indicates that daily prune consumption may improve the gut fecal microbiome of postmenopausal women. The fecal microbiome – the ecosystem of microorganisms found in one's fecal matter – reflects an individual's overall gut health. Results from the study showed notable enrichment in bacteria from the family Lachnospiraceae. This group of bacteria has been associated with an ability to decrease inflammatory markers in the body and help maintain the integrity of the gut barrier.

16 Feb 2023

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.

15 Feb 2023

Study charts seasonal and circadian genetic variation across the human body

The daily rotation of Earth and its yearly voyage around the Sun marks the natural rhythm of life on the planet.

14 Feb 2023

Blastocystis can promote or disrupt gut health, study finds

The gut microbiota contains trillions of bacteria that can promote health or cause disease under different conditions.

14 Feb 2023

Oral difelikefalin could reduce the intensity of itch in patients with notalgia paresthetica

Notalgia paresthetica-;a nerve disorder characterized by a persistent itch in the upper back-;is a common and underdiagnosed condition worldwide.

9 Feb 2023

Strata Oncology publishes study validating integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).

8 Feb 2023

Treating ovarian cancer with immunotherapy involving CAR T cells

Recent research revealed that CAR T-cell therapy, a particular type of cancer treatment in which the immune system’s T cells are directed to kill tumor cells, is successful in treating ovarian cancer in mice.

7 Feb 2023

CAR T-cell therapy effective in mice with ovarian cancer

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.

6 Feb 2023

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Cerba Research announced today a Memorandum of Understanding with Teddy Clinical Research Laboratory (Wuxi, China), a preeminent central lab provider covering mainland China, to lay the foundation for an in-depth discussion towards the creation of a Joint Venture.

From Cerba Research 3 Feb 2023

AI-based strategy helps discover high-affinity antibody drugs

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

31 Jan 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Major development in re-treatment with CAR T therapy

At the American Society of Hematology (ASH) Annual Meeting in 2022 (Abstract 2016), researchers from the Abramson Cancer Center at the University of Pennsylvania presented preliminary findings from an ongoing Phase I clinical trial demonstrating effective re-treatment with CAR T cell therapy for patients whose cancers relapsed after prior CAR T therapy.

12 Dec 2022

Revealing the unappreciated role of POLQ in responding to DNA replication stress

Researchers at the Francis Crick Institute, in partnership with Artios, have discovered how an enzyme involved in DNA repair (POLQ) becomes critical to the survival of some tumors when the cancer cells lose the ability to employ a more frequent way of DNA repair.

1 Dec 2022

Importance of localizing BRCA gene mutations for ovarian cancer treatment

Mutations in the BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 persons, respectively, elevate the risk of various malignancies such as ovarian, breast, pancreatic, and prostate cancer considerably.

30 Nov 2022

Treatment using CRISPR alleviates swelling attacks in hereditary angioedema patients

Hereditary angioedema (HAE) is a rare, genetic disorder characterized by severe, recurring, and unpredictable swelling attacks in various organs and tissues of the body, which can be painful, debilitating, and life-threatening.

11 Nov 2022

Novel high-resolution taxonomy facilitates effective management of CRC patients

Recent research discovered that bowel tumors can be classified into six clinically relevant subcategories based on patterns of gene interactions seen within tumor cells. The study was published in eLife.

10 Nov 2022

New drug to tackle complex cases of UTI

A new drug combination has been shown to be more successful, especially against persistent, drug-resistant infections, according to an international study conducted by a Rutgers Researcher comparing new and older therapies for complex urinary tract infections.

From Rutgers University 28 Oct 2022

Genome Editing Has A New Code

In this interview, we speak to Samantha Maragh, the leader of the genome editing program at NIST, about the genome editing vocabulary and what this means for researchers worldwide.

From National Institute of Standards and Technology (NIST) 21 Oct 2022

Adults with congenital blindness experience striking recoveries of night vision after gene therapy

Adults with a genetic form of childhood-onset blindness experienced striking recoveries of night vision within days of receiving an experimental gene therapy, according to researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania.

11 Oct 2022